ELIQUIS Resources for Your Practice

Request Samples

ELIQUIS® (apixaban) 5 mg tablets are available for eligible prescribers. If you are a prescriber, check to see if you are eligible to have samples delivered to your office.

ELIQUIS 360 Support provides a dedicated phone line
(1-855-ELIQUIS [354-7847]) available to patients, physicians, and staff

  • The line is staffed by agents, available Monday–Friday, 8 AM to 8 PM EST
  • Agents can assist with questions and matters related to benefit coverage and card activations

The Reimbursement Services Program for ELIQUIS can help with:

  • Patient benefit review summaries
  • Provide plan-specific form for prior authorizations when needed
  • General information on formulary exception requests and tiering exception requests
  • General information on appeals process

Fax completed benefit review forms to 1-855-674-8134

  • Provider Portal

Physicians and their staff can visit www.eliquis360providerportal.com to:

  • Track patients’ prescription coverage status in real time
  • Communicate through a secure server about patient benefit review requests
  • Download and submit benefit review form on behalf of patients and upload Patient Authorization and Agreement (PAA) Forms to the patient record (patients must sign the PAA Form first)
  • Run reports displaying prescription coverage status of all patients by provider

Help Your Patients Get Started on ELIQUIS*

Your patients may be eligible for a free 30-day trial and a $10 co-pay card for their ELIQUIS prescriptions. To get ELIQUIS free trial and co-pay cards for your patients, please contact a representative.

*Terms and conditions apply. See the terms and conditions

$10 CO-PAY CARD ELIGIBILITY REQUIREMENTS:

You may be eligible for the Co-pay Card for ELIQUIS® (apixaban) if:

  1. You are insured by commercial insurance and your prescription insurance coverage does not cover the full cost of your prescription, that is, you have a co-pay obligation for ELIQUIS;
  2. You do not have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), or Department of Defense (DOD) programs; patients who move from commercial plans to state or federal healthcare programs will no longer be eligible;
  3. You are 18 years of age or older; and
  4. You are a resident of the United States or Puerto Rico.

$10 CO-PAY CARD TERMS OF USE:

30-DAY FREE TRIAL OFFER ELIGIBILITY REQUIREMENTS:

You may be eligible for the Free 30-Day Trial Offer for ELIQUIS® (apixaban) if:

  1. You have not previously filled a prescription for ELIQUIS;
  2. You have a valid 30-day prescription for ELIQUIS;
  3. You are being treated with ELIQUIS for an FDA-approved indication that an HCP has planned for more than 35 days of treatment;
  4. You are 18 years of age, or older; and
  5. You are a resident of the United States or Puerto Rico.

30-DAY FREE TRIAL OFFER TERMS OF USE:

  1. Eligible patients who present a Free 30-Day Trial card together with a valid 30-day prescription for ELIQUIS at participating pharmacies can receive a free 30-day supply (up to 74 tablets) of ELIQUIS. Patient is responsible for applicable taxes, if any. This offer may not be redeemed on prescriptions written for longer than 30 days.
  2. This offer is limited to one use per patient per lifetime and is non-transferable. By redeeming this offer, you certify that you have not previously filled a prescription for ELIQUIS.
  3. The Free 30-Day Trial for the specified prescription cannot be combined with any other rebate/coupon, free trial, or similar offer. No substitutions are permitted.
  4. Patients, pharmacists, and prescribers cannot seek reimbursement for the Free 30-Day Trial of ELIQUIS from health insurance or any third party, including state or federally funded programs.
  5. Patients may not count the Free 30-Day Trial of ELIQUIS as an expense incurred for purposes of determining out-of-pocket costs for any plan, including true out-of-pocket costs, (“TrOOP”), for purposes of calculating the out-of-pocket threshold for Medicare Part D plans.
  6. Activation and use of the Free 30-Day Trial card must take place by December 31, 2019. This card expires on December 31, 2019.
  7. Only valid in the United States and Puerto Rico; this offer is void where restricted or prohibited by law.
  8. Bristol-Myers Squibb and Pfizer reserve the right to rescind, revoke, or amend this offer at any time without notice.
  9. This Free 30-Day Trial card may not be sold, purchased, traded, or counterfeited. Reproductions of this card are void.
  10. This offer is not conditioned on any past, present, or future purchase, including refills.
  11. The ELIQUIS Free 30-Day Trial offer is not health insurance.

BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

To the pharmacist: For processing assistance, please call McKesson Pharmacy Support at 1-866-279-4730.

Image of the downloadable dosing guide with dosing information for this anticoagulant

ELIQUIS Dosing Guide

This downloadable dosing guide contains important ELIQUIS dosing information for all of the approved indications.

Reprints of selected ELIQUIS Clinical Trial Studies

Download* clinical trial studies for ELIQUIS.

*To download these articles you will be directed to websites that may not be affiliated with Bristol-Myers Squibb or Pfizer. Bristol-Myers Squibb and Pfizer are not responsible for the content of such other sites. Links to other sites are provided only as a convenience to users of this site.

Reduction in the Risk of Stroke/Systemic Embolism in NVAF:

Treatment of DVT/PE:

Reduction in the Risk of Recurrent DVT/PE Following Initial Therapy:

IMPORTANT SAFETY INFORMATION

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA

(A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.

(B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

  • use of indwelling epidural catheters
  • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
  • a history of traumatic or repeated epidural or spinal punctures
  • a history of spinal deformity or spinal surgery
  • optimal timing between the administration of ELIQUIS and neuraxial procedures is not known

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.

CONTRAINDICATIONS

  • Active pathological bleeding
  • Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)

WARNINGS AND PRECAUTIONS

  • Increased Risk of Thrombotic Events after Premature Discontinuation: Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
  • Bleeding Risk: ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.

    • Concomitant use of drugs affecting hemostasis increases the risk of bleeding, including aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs.
    • Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.
    • There is no established way to reverse the anticoagulant effect of apixaban, which can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). A specific antidote for ELIQUIS is not available.
  • Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis.

    The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours.

    Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

  • Prosthetic Heart Valves: The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients.
  • Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy: Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

ADVERSE REACTIONS

  • The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding.

TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS

  • ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.

DRUG INTERACTIONS

  • Combined P-gp and Strong CYP3A4 Inhibitors: Inhibitors of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) increase exposure to apixaban and increase the risk of bleeding. For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or ritonavir). In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with combined P-gp and strong CYP3A4 inhibitors. Clarithromycin Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration with ELIQUIS.
  • Combined P-gp and Strong CYP3A4 Inducers: Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban.
  • Anticoagulants and Antiplatelet Agents: Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.

PREGNANCY CATEGORY B

  • There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.
INDICATIONS

ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

ELIQUIS is indicated for the treatment of DVT and PE, and to reduce the risk of recurrent DVT and PE following initial therapy.

Please see U.S. FULL PRESCRIBING INFORMATION including Boxed WARNINGS, and MEDICATION GUIDE.

ELIQUIS is available in 2.5 mg and 5 mg tablets.

SELECTED IMPORTANT SAFETY INFORMATION

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS,(B) SPINAL/EPIDURAL HEMATOMA

(A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.

See Full Boxed WARNINGS

ELIQUIS® and the ELIQUIS logo are trademarks of Bristol-Myers Squibb Company. All other trademarks are the property of their respective owners.
© Bristol-Myers Squibb Company. 432US1801092-01-01  04/18